MRTX-1719 is a highly potent and selective small molecule inhibitor of the PRMT5-MTA complex, demonstrating sub-10 nM IC50 activity in relevant cellular models. Its application facilitates research in oncology, particularly for investigating MTAP-deleted cancers in both in vitro and in vivo experimental settings.